Zoetis Inc. (NYSE:ZTS) EVP Heidi C. Chen Sells 9,905 Shares of Stock

Zoetis Inc. (NYSE:ZTS) EVP Heidi C. Chen sold 9,905 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $180.15, for a total value of $1,784,385.75. Following the completion of the sale, the executive vice president now owns 27,478 shares in the company, valued at $4,950,161.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Zoetis Stock Performance

ZTS opened at $179.65 on Tuesday. Zoetis Inc. has a 52-week low of $124.15 and a 52-week high of $194.99. The company has a quick ratio of 1.97, a current ratio of 3.50 and a debt-to-equity ratio of 1.42. The company has a market cap of $82.70 billion, a P/E ratio of 37.74, a price-to-earnings-growth ratio of 2.94 and a beta of 0.78. The firm’s 50-day moving average price is $183.65 and its 200-day moving average price is $175.28.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.10. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.16 billion. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.20 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 5.42 EPS for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price objective on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Monday, August 14th. HSBC began coverage on shares of Zoetis in a research note on Wednesday, September 6th. They set a “buy” rating and a $230.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $205.00 price objective on shares of Zoetis in a research note on Tuesday, September 12th. Finally, StockNews.com upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $225.13.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aspire Private Capital LLC purchased a new stake in shares of Zoetis in the first quarter worth about $15,019,213,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares during the last quarter. VitalStone Financial LLC purchased a new stake in shares of Zoetis in the first quarter worth about $37,000. Evermay Wealth Management LLC boosted its stake in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Finally, Pacifica Partners Inc. grew its position in Zoetis by 76.9% during the second quarter. Pacifica Partners Inc. now owns 161 shares of the company’s stock valued at $27,000 after buying an additional 70 shares during the period. Hedge funds and other institutional investors own 89.47% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.